LAUSR

Epithelial ovarian cancer is the fourth most common cause of cancer-related death among women worldwide. Over 220,000 woman are diagnosed with epithelial ovarian cancer every year, with the incidence of the disease estimated to be 5 per 100,000 people.1 According to asymptomatic in early stage disease, over 80% of patients have symptoms even when the disease is widely metastatic to abdominal lumen.2 The overall survival rate of patients with ovarian cancer has improved from 36% to 46% due to taxane and platinum chemotherapies.3 Yet chemotherapeutic agents can cause side effects and are only able to prolong five-year survival rates for patients with an advanced stage of the disease—such as stage IIIC— for a mere 39% of patients.4 New effective treatment is therefore crucial to improve survivability and should be subject to intensive study.